Navigation Links
Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
Date:5/18/2010

CALGARY, AB, May 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that a paper entitled "Two-Stage Phase I Dose-Escalation Study of Intratumoural Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers," has been published in the online version of the journal Clinical Cancer Research.

The paper covers final results from a Phase Ia/Ib U.K. clinical trial (REO 006) investigating the intratumoural delivery of REOLYSIN(R) in combination with radiation to treat patients with advanced cancers. A total of 23 patients received a range of two to six intratumoural doses of REOLYSIN at escalating dosages up to a maximum of 1x10(10) TCID(50) with a constant localized radiation dose of either 20 Gy or 36 Gy. The principal investigator for the study is Dr. Kevin Harrington from The Institute of Cancer Research and The Royal Marsden Hospital, London, U.K.

Of the seven evaluable patients in the low-dose (20Gy) radiation group, two patients had a partial response (PR) (esophageal adenocarcinoma and squamous cell carcinoma (SCC) of the skin) and five had stable disease (SD) including patients with malignant melanoma, pancreatic adenocarcinoma, SCC of the larynx and SCC of the skin (2). In the high-dose (36Gy) radiation group, five of seven evaluable patients had PRs (malignant melanoma (2), lung adenocarcinoma, colorectal adenocarcinoma, and ovarian adenocarcinoma) and two had SD (malignant melanoma).

"All 14 patients considered evaluable for treatment response in this study had SD or better for a clinical benefit rate of 100%," said Dr.

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
2. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
3. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
4. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
5. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
6. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
7. Oncolytics Biotech(R) Inc. Announces Unit Offering
8. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
9. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
10. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)...  Personal Genome Diagnostics Inc. (PGDx), today announced ... expertise in genomic analysis of defined cancer subtypes ... Blueprint Medicines.  PGDx is an innovator in conducting ... tumors, and Blueprint Medicines is an expert in ... defined patient population. "This collaboration brings ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
(Date:5/21/2013)... Inflamax scientists worked closely with ... design the study, which will provide critical insight ... used in the study of allergy treatments, the ... (NAC) models. Although both the models are well ... no direct comparison between the allergic responses evoked ...
(Date:5/21/2013)... 2013 Possible mold re-infestation in Guilemtte School ... a report from eagletribune.com posted May 14, 2013, the state ... result is positive, My Cleaning Products offered a tip ... , It was said in the Eagle Tribune report (5.14.13) ... campus sparked after a first-grade classroom was closed due to ...
Breaking Biology Technology:Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3
... Life Sciences, Inc. (NASDAQ: SRLS ), a ... to facilitate the discovery, development and production of human ... 2011 fiscal fourth quarter and year ended September 30, ... fourth quarter, we drove an improvement in the direction ...
... Nov. 16, 2011 Oligomerix, Inc. presented results ... D.C. which demonstrated that tau protein forms neurotoxic ... proteolytic function results in tau,s self-fragmentation and in ... for its neurotoxic mode-of-action. Furthermore, certain tau oligomer ...
... November 16, 2011 We want to protect our ... the digital share of our lives is growing constantly: we rely ... our personal data and even our fingerprints are stored online. ... or simply use our computer or mobile phone… Identity thieves could ...
Cached Biology Technology:SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 2SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 3SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 4SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 5SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results 6A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting 2AGSES - Your Key to Online Freedom 2
(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... pharmacies and health stores, phosphatidylserine is a natural ... Proven to improve cognition and slow memory loss, ... memory impairment. Now a team headed by Prof. ... Aviv University,s Department of Human Molecular Genetics ... the functioning of genes involved in degenerative brain ...
(Date:5/21/2013)... gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... resource assessment, market and policy developments, manufacturing and installation, ... and benefiting from its 2013 edition from a record ... 60 countries, more than 240 plenary and oral presentations, ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... University in St. Louis paleoanthropologist Glenn Conroy, PhD, discovered the ... known pre-human ape ever found south of the equator in ... in Namibia. Traditionally, fossil-hunters often could only make educated ... chance finding the proverbial needle in a haystack. ...
... University of Texas at Dallas are examining whether multiple ... research that could enable new medical interventions against the ... Dr. Tres Thompson, associate professor in UT Dallas, School ... loud noises induces plasticity in the hippocampus, a section ...
... ,A new model developed by scientists of the ... presence of bluefin tuna to be tracked through daily ... illegal fishing. The model, based on satellite remote sensing ... of the preferred bluefin tuna habitats in the Mediterranean ...
Cached Biology News:Human, artificial intelligence join forces to pinpoint fossil locations 2UT Dallas research widens study of brain's role in tinnitus 2Satellite data can help protect bluefin tuna 2
... Immunogen: Synthetic peptide derived from the ... Specificity: Specific for the internall ... Reactivity: Mouse (positive controls: mouse brain ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
...
Fluorescence Preserving Media, 100 mL...
... Custom monoclonal antibody development to targets including ... molecules, DNA, and cancer-specific surface antigens. ... and is completed in approximately 40 days ... nature of antigens). Phase I: Immunization, ...
Biology Products: